Skip to main content
Premium Trial:

Request an Annual Quote

Cofactor Genomics Acquires Narus Biotechnologies

NEW YORK (GenomeWeb) – RNA products developer Cofactor Genomics announced today that it has acquired San Francisco-based biomarker development company Narus Biotechnologies.

The acquisition of Narus — which has been focused on creating RNA-based diagnostics for neurological diseases such as Alzheimer's and Parkinson's — will help Cofactor to further expand into the realm of RNA diagnostics, and to develop its plans to create RNA-based tests for cancer and neurodegenerative diseases, the company said.

Terms of the deal were not disclosed.

"In addition to acquiring Narus' assets related to RNA biomarkers, we gain an extremely talented team that is already helping to accelerate Cofactor's RNA-based diagnostic roadmap," said Cofactor CEO Jarret Glasscock in a statement. "This acquisition … secures the resources necessary to change the face of medicine by using RNA to detect disease and monitor treatment progression."

Over the past two years, Cofactor has received at least two NIH grants to develop circular RNA enrichment technology and companion data analysis software to detect circRNA as a possible biomarker for psychiatric disorders.